Academic journal article International Perspectives on Sexual and Reproductive Health

HPV Vaccine Protects Women Even Longer

Academic journal article International Perspectives on Sexual and Reproductive Health

HPV Vaccine Protects Women Even Longer

Article excerpt

A vaccine against the two types of human papillomavirus (HPV) most closely linked to cervical cancer effectively protects young women for more than six years against infection and the development of precancerous cervical lesions, according to an extended follow-up of an initial three-year clinical trial conducted in Brazil, Canada and the United States. (1) Of the 1,113 healthy 15-25-year-old women who tested negative at baseline for HPV, half were randomized to receive the vaccine against HPV types 16 and 18, and half to receive a placebo; participants in both groups provided cervical and blood samples at six-month follow up visits for cytological and DNA testing. The mean follow-up from the start of the study was 5.9 years; the longest follow-up was 6.4 years. Overall, the vaccine was 95% effective against infection with HPV 16 and 18, and offered substantial protection against other cancer-causing types of HPV (60% against HPV-31, and 78% against HPV-45). In addition, no women who received the vaccine developed a precancerous cervical lesion associated with HIV types 16 and 18 within the study period, for an efficacy of 100%; the efficacy of the vaccine against cervical lesions of any-type was 72%. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.